Join us on 12-15-2022 for a live seminar about RNA SEQ
We offer our technologies and capabilities to the entire drug discovery community—from academic scientists, small and medium biotech, to the largest biopharma—on affordable, non-exclusive terms. This network of collaboration among drug discovery teams creates innovations that are then widely distributed to benefit all.
We’ve grown from our original platform for human monoclonal antibody discovery, the ATX-Gx, to support a spectrum of biologics. Discovery groups find the best drug against their target and develop innovative new therapeutic formats.
We reinvest 100% of our revenue into innovation and access to innovation to continually improve our offering for partners. Our white glove model includes:
PLATFORMS
SERVICES
SUBSCRIPTIONS
We acquire and develop pre-competitive discovery platforms and license them to the global drug discovery community at groundbreaking terms.
Dig into:
Our discovery services team acts as an extension of yours, deploying our proprietary and industry standard suite of technologies to find you the best candidate against your target.
Our flagship:
Our Innovation Subscriptions give you royalty-free, unlimited access to all our current and forthcoming technology.
There is no one-size-fits-all engagement with Alloy. We partner flexibly and creatively across each collaboration, activating our stable of platform technologies, discovery services, and company creation capabilities to meet our partners’ goals.
Leveraged by a community of 100+ partners, the ATX-Gx is our foundational suite of highly immunocompetent transgenic mice for in vivo discovery. The growing suite of strains is engineered to drive the greatest potential diversity of unique human antibodies binding to your target of interest with broad epitopic coverage.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
We are alway expanding our portfolio of innovative, enabling technologies. Platforms in development will support bispecifics and CAR Discovery, innovative combination therapeutics, and machine-learning enabled discovery.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
Explore:
Our research facilities:
Boston, MA
Cambridge, UK
Basel, CH
San Francisco, CA
Athens, GA
© 2023 Alloy Therapeutics, Inc. All Rights Reserved.